<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9872">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688397</url>
  </required_header>
  <id_info>
    <org_study_id>OLIVIA</org_study_id>
    <nct_id>NCT05688397</nct_id>
  </id_info>
  <brief_title>Evaluation of the Vaginal Colonization of Two New Lactobacillus Strains After Oral Administration in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Vaginal Colonization Capacity, Safety, and Tolerability of Two New Strains of L. Gasseri and L. Crispatus When Administered Orally in Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Biotics, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Biotics, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study to determine whether the vaginally isolated strains of Lactobacillus gasseri&#xD;
      and/or Lactobacillus crispatus can colonize the vagina when taken orally for 18 days.&#xD;
      Secondary outcomes comprise evaluation of safety, tolerability, impact on vaginal microbiota&#xD;
      and vaginal pH&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, randomized, placebo-controlled biomedical research study to determine whether&#xD;
      supplementation with the vaginally isolated strains of Lactobacillus gasseri and/or&#xD;
      Lactobacillus crispatus can colonize the vagina. Healthy women who meet inclusion and&#xD;
      exclusion criteria will be randomized 1.5:1.5:1 to one of the following study groups: group&#xD;
      one will receive L.gasseri for 18 days (1 capsule/day), group two will recieve the&#xD;
      combination of L.gasseri and L.Crispatus for 18 days (1 capsule/day) and the other will&#xD;
      receive placebo, starting the day after menstruation is over. Main study outcome will be&#xD;
      colonization throughout the study, which will be determined by analysis of specific strains&#xD;
      by qPCR. Secondary outcomes comprise comprise evaluation of tolerability, impact on vaginal&#xD;
      microbiota, vaginal pH and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2023</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonization of L. crispatus strain in the vagina</measure>
    <time_frame>0,15 or 18 days</time_frame>
    <description>Change in the concentration of L. crispatus strain throughout study period measured by qPCR in samples obtained with vaginal swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colonization of L. gasseri strain in the vagina</measure>
    <time_frame>0,15 or 18 days</time_frame>
    <description>Change in the concentration of L. gasseri strain throughout study period measured by qPCR in samples obtained with vaginal swab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal colonization of L. gasseri strain</measure>
    <time_frame>Day 0, 3, 6, 9, 12, 15</time_frame>
    <description>Change in the vaginal concentration of L. gasseri strain measured by qPCR versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal colonization of L. crispatus strain</measure>
    <time_frame>Day 0, 3, 6, 9, 12, 15</time_frame>
    <description>Change in the vaginal concentration of L. crispatus strain measured by qPCR versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal microbiota composition</measure>
    <time_frame>Day 0, 6, 12 and 15 or 18</time_frame>
    <description>Change in vaginal microbiota composition measured by 16S rRNA sequencing analysis in samples obtained from vaginal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perianal concentration of L. crispatus strain</measure>
    <time_frame>Day 0, 9 and 15 or 18</time_frame>
    <description>Change in the perianal concentration of L. crispatus strain measured by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perianal concentration of L. gasseri strain</measure>
    <time_frame>Day 0, 9 and 15 or 18</time_frame>
    <description>Change in the perianal concentration of L. gasseri strain measured by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal pH</measure>
    <time_frame>Day 0, 3, 6, 9, 12, 15, 18</time_frame>
    <description>Change in vaginal pH throughout study period measured by pH test strip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>day 0, day 18</time_frame>
    <description>Gastrointestinal manifestations measured on a 4-point scale: 0 = none , 1 = mild, 2 = moderate, and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>18 days</time_frame>
    <description>Frequency of adverse events throughout study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the product</measure>
    <time_frame>Day 18</time_frame>
    <description>Evaluation of the satisfaction with the product through the Treatment Satisfaction Questionnaire for Medication (TSQM)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L. gasseri oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L. gasseri + L. crispatus oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin (E1400, qs) oral capsule once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental 1</intervention_name>
    <description>L. gasseri oral capsule once a day (1 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over</description>
    <arm_group_label>Experimental 1</arm_group_label>
    <other_name>Probiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental 2</intervention_name>
    <description>L. gasseri and L. crispatus oral capsule once a day (1.5 x 10^9 CFU/day) for 18 days starting the next day after menstruation is over</description>
    <arm_group_label>Experimental 2</arm_group_label>
    <other_name>Probiotic mixture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women&#xD;
&#xD;
          -  Reproductive age 18-45 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vaginal infection or symptoms (AMSEL criteria).&#xD;
&#xD;
          -  Relevant disease (immunodeficiency, cervicovaginal pathology, diabetes,&#xD;
             estrogen-dependent tumors, inflammatory bowel disease, atrophic vaginitis,&#xD;
             pancreatitis)&#xD;
&#xD;
          -  Suffer from chronic diarrhea or constipation or short bowel syndrome,&#xD;
&#xD;
          -  Having taken systemic or vaginal antibiotics or antifungals during the month prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Pregnant women or willing to be during the study, lactating women.&#xD;
&#xD;
          -  Having taken another probiotic during the month prior to study entry orally or&#xD;
             vaginally. This includes food supplements or foods supplemented with probiotics such&#xD;
             as Actimel, Activia or similar.&#xD;
&#xD;
          -  Intake of immunomodulators or systemic corticosteroids.&#xD;
&#xD;
          -  History of alcohol or drug abuse.&#xD;
&#xD;
          -  Menopausal women.&#xD;
&#xD;
          -  Use of the IUD.&#xD;
&#xD;
          -  Use of spermicides or vaginal lubricants during the month prior to study entry.&#xD;
&#xD;
          -  Very irregular periods or low probability of going at least 18 days without&#xD;
             menstruation (short cycles).&#xD;
&#xD;
          -  Have participated in a clinical trial during the month prior to entering the study.&#xD;
&#xD;
          -  Not being able to follow or understand study procedures. This includes not being&#xD;
             willing to maintain sexual abstinence during the 24 hours prior to each vaginal sample&#xD;
             collection.&#xD;
&#xD;
          -  Any other condition not compatible with the study according to the investigators&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Maria Aldea Perona, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Hospital del Mar de Investigaciones Médicas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Maria Aldea Perona, PhD</last_name>
    <phone>0034 93 3160490</phone>
    <email>aaldea@imim.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Hospital del Mar de Investigaciones Médicas</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria Aldea Perona, PhD</last_name>
      <email>aaldea@imim.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

